Wedbush raised the firm’s price target on Neurocrine (NBIX) to $151 from $149 and keeps an Outperform rating on the shares following quarterly results. While Crenessity revenue guidance was not yet provided, the firm notes Ingrezza revenue guidance took four years to materialize.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $173 from $175 at Morgan Stanley
- Reaffirming Buy: Solid Core Franchise Execution and Underappreciated Pipeline Upside Support Mid-$150s Valuation
- Neurocrine Biosciences: Durable Ingrezza Franchise and Emerging Crenessity Uptake Support Buy Rating and $190 Price Target
- Neurocrine price target raised to $204 from $203 at Citi
- Neurocrine price target lowered to $192 from $198 at H.C. Wainwright